Allergan's stock has taken a hit since news of laViv approval…
The posts on this board about AGN’s purported concern with laViv are utterly comical.
What has weighed on AGN the past two days is not laViv, but rather than FDA’s findings on the safety of silicone breast implants based on the post-marketing studies conducted by AGN and JNJ.